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Abstract
Pediatricanxietydisordershavehighprevalenceratesandmorbidityandareassociatedwithconsiderable
functional impairment and distress. They may be predictors for the development of other psychiatric
disorders and, without intervention, are more likely to persist into adulthood. While evidence-based
pharmacological and behavioral interventions are currently available, there remains a sizable subset of
youth who remain only partially treatment-responsive and therefore symptomatic following treatment.
Novel methods of treatment, pharmacologic and non-pharmacologic, including acceptance and
commitment therapy (ACT), attention bias modification (ABM), d-cycloserine (DCS) augmentation of
cognitive behavioral treatment (CBT), and glutamatergic agents such as riluzole, are briefly introduced
and discussed.
Introduction and context
Anxiety disorders in the pediatric population occur
frequently, with prevalence rates of 10% to 20% [1,2].
While developmentally appropriate worry and fear are
common in children and adolescents, clinically signifi-
cant levels of anxiety can be chronic and disabling [3].
Pediatric anxiety disorders have high levels of comorbid-
ity with other anxiety disorders, depression, and dis-
ruptive behavior disorders and are associated with
significant psychosocial impairment as well as increased
likelihood of substance abuse and suicidal behavior
[3-8]. When left untreated, anxiety in childhood is a
predictor for anxiety disorders and major depression
later in life [7].
CBT and selective serotonin reuptake inhibitors (SSRIs)
have emerged as the most empirically robust treatment
modalities for pediatric anxiety disorders [9]. Monother-
apy and combination therapy (SSRIs + CBT) have been
demonstrated to be efficacious in large comparative trials;
one multisite study reported treatment response rates
of 81% for sertraline + CBT combination therapy, 60%
for CBT monotherapy, and 55% for sertraline mono-
therapy, relative to a 24% response rate for placebo [10].
While CBT and SSRIs are considered first-line treatment
for youth with anxiety, up to 50% continue to meet
criteria for anxiety disorder after treatment [1,2,11]. For
thisreason,researchhas soughtmethods bothtoaugment
currently available treatments as well as to develop
alternative modalities to treat pediatric anxiety disorders.
This report presents emerging evidence for new treatment
methods that have shown promising results as potential
interventions for youth with anxiety disorders (Table 1).
Non-pharmacological interventions
Acceptance and commitment therapy
The extant literature regarding ACT has demonstrated
empirical efficacy. Favorable results in adult trials [12,13]
have spurred discussion regarding the application and
utility of ACT for the treatment of pediatric anxiety
disorders. Whereas CBT focuses on the content of
cognitions and seeks to alter these thoughts, ACT is
concerned about the process and function of thoughts
in specific contexts [14,15]. ACT seeks to increase
psychological flexibility through cognitive defusion and
acceptance [14]. Individuals are encouraged to recognize
thoughts as simply thoughts, which are not necessarily
rooted in reality or truth [16]. Additionally, experiential
Page 1 of 6
(page number not for citation purposes)
Published: 06 May 2014
© 2014 Faculty of 1000 Ltdavoidance, which is defined as the avoidance of specific
experiences (e.g. thoughts, emotions, and physiological
sensations), is considered unproductive and counter to
acceptance. Rather than direct symptom reduction, the
goal of treatment is to engage in behaviors that will
facilitate living a life that reflects the individual’sv a l u e s ,
and as a side effect of this goal, symptoms associated with
psychiatric disorders may subside [17].
Arguments against using ACT in the pediatric population
note that requisite concepts are too complex and abstract
for children and adolescents to grasp. However, several
reports note the successful application of ACT in the
treatment of various pediatric populations [18-20].
Studies have also demonstrated that therapy based on
mindfulness (which is a core component of ACT) is
effective in reducing anxiety symptoms in children and
adolescents [21,22]. Still, a dearth of empirical research
has specifically examined ACT for pediatric anxiety
disorders. In a case study, the anxiety and obsessive
thoughts of an 18-year-old female with moderate mental
retardation were treated with a 17-session ACT protocol
that was modified for her developmental level [23].
Following treatment, the patient experienced decreased
experiential avoidance, increased social confidence, and
decreased duration of anxiety “episodes”.C u r r e n t l y ,a
randomized controlled study is under way to examine the
efficacyofACT relativetoCBT andwait-list controlgroups
delivered via group therapy in the treatment of pediatric
anxiety disorders [24]. This study will elucidate both the
feasibility and efficacy of ACT in treating pediatric anxiety
disorders and will help clinicians determine the best
course of treatment for this population.
Attention bias modification
Attention biases toward threat-related stimuli are postu-
lated to contribute to the etiology and maintenance of
anxiety disorders [25,26]. Because of this, research has
strivedtoimplementABMtechniquestoretrainattention
biases away from threat. Most frequently, a computer-
based dot-probe task is used, and the difference in
response times in the identification of a visual probe
whenpairedwiththreateningorneutralstimuliisusedas
the attention bias index [27,28]. Faster response times
when the threatening stimuli are presented indicate an
attention bias toward threat; these findings have been
consistently demonstrated in both adults and children
with anxiety [25,29,30]. ABM then implicitly retrains
attention away from threatening stimuli by repeatedly
presenting the visual probe over the neutral stimuli.
Computerized ABM provides a systematic intervention
that may be more palatable for youth who may find
standard CBT or psychotherapy to be aversive.
Several studies have examined the efficacy of ABM in
children with anxiety. In a study of chronically anxious
children (mean age of 10 years), 2 sessions of ABM
resulted in increased attention disengagement from
threat, and anxious children were better able to shift
their attention away from threatening stimuli [31]. In
a randomized controlled trial (RCT) with clinically
anxious children (ages 8 to 14 years) with primary
separation anxiety, social phobia, or specific phobia,
four sessions of ABM were successful in reducing clinician
severity ratings of pediatric anxiety symptoms [32]. A
case series reported downward trends of anxiety ratings
from pre- to post-treatment following 8 sessions of ABM
with anxious children who were deemed non-responders
to a 12- to 14-week trial of CBT [33].
The clinical utility of ABM as an adjunct to CBT has also
been examined. In a study of youth ages 13 to 17 years in
a residential unit for severe anxiety, those who received
ABM in addition to daily (weekday) CBT had significantly
Table 1. Published reports on novel non-pharmacological intervention for anxiety disorders in youth
Targeted symptoms Treatment Author Design Post-treatment results
Anxiety and obsessive thoughts ACT Brown and Hooper [23] Case study; n = 1; age:




duration of anxiety episodes
Chronic anxiety ABM Bar-Haim et al. [31] RCT; n = 34; ages:
8-14 years; 2 sessions
Reduction in threat bias in
ABM group
Separation anxiety, social
phobia, specific phobia, and
generalized anxiety disorder
ABM Eldar et al. [32] RCT; n = 40; ages:
8-14 years; 4 sessions
ReductioninthreatbiasinABM
group; significant reductions in
anxiety symptoms in ABM




ABM-adjunctive CBT Bechor et al. [33] Case series, n = 6; ages:
13-17 years; 8 sessions
Baselinethreatbiasnotuniform
in group; significant reductions
in child-rated anxiety and
parent-rated anxiety
ABM, attention bias modification; ACT, acceptance and commitment therapy; CBT, cognitive behavioral therapy; RCT, randomized controlled trial.
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relative to those who received CBT alone [34]. A recent
RCT examined the efficacy of ABM-augmented CBT rela-
tive to placebo-augmented CBT and CBT monotherapy.
Whereas both ABM and placebo groups showed signifi-
cantly greater reductions in clinical ratings relative to
the CBT-only group, only the active ABM group had




Central glutamatergic systems have been implicated in
the pathophysiology of various anxiety disorders [36].
N-methyl-D-aspartate (NMDA) subtype glutamate
receptor-mediated facilitation in the basolateral amyg-
dala has been suggested as a potential mechanism for the
more rapid acquisition and retention of fear extinction.
NMDA receptors have an established role in the
induction of many forms of neuroplasticity best seen in
long-term potentiation (LTP) [37-41]. In sum, glutama-
tergic activity at the NMDA receptor seems to be critically
involved in the neural mechanisms of learning and
memory [42]. Therefore, interest in pharmacological
agents that target glutamatergic sites has increased in
recent years.
Riluzole
Riluzole, an anti-glutamatergic agent, has been examined
for its anxiolytic effects on anxiety disorders [43]. Several
open-label trials in adults examining riluzole as mono-
therapy or an adjunct therapy have resulted in significant
reductions in anxiety symptoms after treatment [44,45].
Amongstudieswithyouth,riluzoleas anaugmentation to
pharmacotherapy was examined in a 12-week open-label
study for children (ages 8 to 16 years) with treatment-
resistant obsessive-compulsive disorder (OCD) [46]. At
post-treatment, substantial OCD symptom reduction was
found in 4 out of the 6 participants. However, a 12-week
RCT of adjunctive riluzole among 60 treatment-resistant
youth (ages 7 to 17 years old) with OCD failed to find
significant differences between riluzole and placebo-
augmented groups; however, this may be due to
methodological limitations (e.g. sample characteristics
and high rates of concomitant medications) [47]
D-cycloserine
In the treatment of specific anxiety disorders, particularly
OCD, a core component of therapy is exposure and
response prevention (E/RP). In E/RP, individuals are
systematically exposed to fearful stimuli and prevented
from engaging in unhelpful behaviors that will reduce
anxiety (e.g. compulsions and avoidance behaviors).
Repeated exposure to the fearful stimuli facilitates fear
extinction, in which over time, the individual eventually
experiences habituation (i.e. substantial decrease in anxiety
by the end of the exposure) [48]. Although CBT with E/RP
is a robust and efficacious treatment for pediatric OCD
[49,50], recent studies have focused on ways to augment
E/RP with DCS. DCS is an NMDA partial agonist that has
been shown to enhance fear extinction learning in both
animals and humans [51-53]. In adult trials, DCS
demonstrated augmenting effects in the treatment of
specific phobia of heights, social phobia, panic disorder,
and OCD [54-59]. Additionally, DCS increased the
overall speed of treatment effects; in a study of adults
with OCD, those in the DCS group had reductions in
symptoms six times faster in the first half of treatment
relative to those who did not receive DCS [60].
In youth, only one published study has examined DCS as
an adjunct to E/RP [61]. Amongst children with OCD (ages
8 to 17 years), no significant differences were found
between the DCS-augmented E/RP group and the CBT-
alone group; however, the DCS-augmented E/RP group
showedsmalltomoderate treatmenteffects(d= 0.31-0.47)
on primary OCD outcome measures. Currently, a National
Institute of Mental Health-funded multi-site study is being
conducted to further examine the augmenting effects of
DCS with E/RP in children with OCD. The study seeks to
recruit 150 youth between the ages of 7 to 17 years and will
provide important information regarding the incremental
effectiveness of adjunctive DCS with E/RP in a pediatric
population.
DCS is a well-tolerated pharmacological agent. Among
the eight human studies using DCS as an adjunct to
psychotherapy, there have been few to no adverse events
[57,59,61,62]. Additionally, DCS may be particularly
useful when rapid treatment gains are needed. Based on
favorable findings in the literature, further research in
the augmenting effects of DCS for behavioral treatment
in other pediatric anxiety disorders is warranted.
Conclusions
Efficacious and safe methods of treatment are available
for youth with anxiety disorders. However, a subset of
children do not benefit from standard pharmacotherapy
andbehavioralinterventions.Novelapproachesareneeded
to provide alterative options for (partially) treatment-
resistant youth, including pharmacological and
non-pharmacological methods. Translational neuroscience
is expected to open new avenues for treatment interven-
tions in the next decade.
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